We found for
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
